Humanin is a mitochondrial-derived peptide studied for cytoprotection, aging biology, and disease-related biomarkers 5 7. Chia does not offer Humanin, so this guide is education-only. We have not verified any FDA-approved Humanin treatment use. The supplied human evidence includes trials that measure Humanin, but it does not establish consumer dosing, benefits, or safety as a prescribed treatment.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
Humanin is commonly described as a mitochondrial-derived peptide, or MDP: a small peptide linked to mitochondria, the energy-making parts of cells. It is also shortened to HN in research writing. In this evidence set, Humanin is being studied mainly as a biomarker or possible mediator in human disease and stress-response research, not as a proven consumer treatment.
Mitochondrial-derived peptides are a broader group of small signaling peptides connected to mitochondrial biology. If you want the bigger picture, our guides to mitochondrial-derived peptides and mitochondrial peptides explain how Humanin fits beside peptides such as MOTS-c.
The supplied evidence includes a randomized trial in people with type 2 diabetes that evaluated redox-sensitive microRNAs and Humanin as possible mediators of exercise and astaxanthin effects on oxidative stress and inflammation 1. That is important, but it is not the same as showing that giving Humanin improves weight, blood sugar, longevity, kidney outcomes, or heart outcomes.
Mechanism of action
The honest answer is that Humanin’s treatment mechanism in humans is not established by the supplied evidence set. The records here support Humanin as a measured peptide or possible mediator in research settings, with 2025 randomized evidence in type 2 diabetes focused on oxidative stress and inflammation pathways 1.
In plain language, a mediator is a possible link in a chain: an intervention may affect a biological marker, and that marker may relate to a disease process. But a mediator signal does not prove that taking the mediator as a drug will create the same effect.
That distinction matters. For example, the Basereh trial title states that redox-sensitive microRNAs and Humanin could mediate effects of exercise and astaxanthin on oxidative stress and inflammation in type 2 diabetes 1. It does not establish Humanin as a prescribed therapy for type 2 diabetes, inflammation, weight management, or aging.
Evidence
Humanin is assigned evidence grade A in the supplied source registry. That sounds strong, but the grade is based on a broad search that can include unrelated short-name matches; it is not a verdict that Humanin works or is safe as a treatment.
What the supplied randomized trial evidence can and cannot support
The most relevant supplied randomized trial evaluated Humanin in the context of exercise, astaxanthin, oxidative stress, inflammation, and type 2 diabetes 1. Based on the supplied record, it can support a cautious statement that Humanin is being studied in human metabolic and redox biology.
It cannot support a claim that Humanin causes weight loss, improves insulin resistance, protects kidneys, lowers heart risk, slows aging, or extends human life. Those are treatment claims, and the supplied evidence does not establish them.
Why biomarker findings are not the same as proven treatment effects
A biomarker is a measurable signal, like a blood level, protein, peptide, or gene-related marker. Registered studies are measuring Humanin in acute kidney injury, renal transplantation, and cardiac operation contexts 2 3 4.
These studies show that researchers think Humanin may be useful to measure. They do not, by themselves, prove that giving Humanin changes clinical outcomes.
| Question | What the supplied evidence supports | What it does not establish |
|---|---|---|
| Is Humanin studied in humans? | Yes. The supplied sources include a randomized trial involving Humanin-related biomarker research and registered human studies 1 2 3 4. | It does not establish Humanin as a treatment. |
| Is Humanin studied in metabolic health? | Yes. One randomized trial title links Humanin to exercise, astaxanthin, oxidative stress, inflammation, and type 2 diabetes 1. | It does not prove Humanin improves weight, glucose, or diabetes outcomes. |
| Is Humanin studied in kidney or surgery settings? | Yes. Registered studies include acute kidney injury, renal transplantation, and cardiac operation topics 2 3 4. | It does not prove Humanin prevents complications or improves recovery. |
| Is there a clear consumer dosing range? | No human dosing range is established from the supplied records. | No patient dosing instructions can be inferred. |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2023 | Randomised controlled trial | Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer's disease | Alzheimer's research & therapy | PMID 37730689 |
| 2022 | Randomised controlled trial | Five-year Randomized Clinical Trial on the Performance of Two Etch-and-rinse Adhesives in Noncarious Cervical Lesions | Operative dentistry | PMID 34963006 |
| 2022 | Randomised controlled trial | Cytology-based Cancer Surgery of the Head and Neck (CyCaS-HN): a prospective, randomized, controlled clinical trial | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | PMID 35305137 |
| 2021 | Randomised controlled trial | [Acupuncture and moxibustion for vascular dementia and its effect on serum VEGF and AChE] | Zhongguo zhen jiu = Chinese acupuncture & moxibustion | PMID 34369693 |
| 2025 | Randomised controlled trial | Impact of an Electronic Patient-Reported Outcome-Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Rand | JCO oncology practice | PMID 41118619 |
| 2018 | Randomised controlled trial | [Special penetration needling for refractory peripheral facial paralysis] | Zhongguo zhen jiu = Chinese acupuncture & moxibustion | PMID 29701044 |
| 2015 | Randomised controlled trial | Inspiratory muscle training during pulmonary rehabilitation in chronic obstructive pulmonary disease: A randomized trial | Chronic respiratory disease | PMID 26170421 |
| 2025 | Randomised controlled trial | Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study | Dermatology (Basel, Switzerland) | PMID 39476813 |
| 2025 | Randomised controlled trial | Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | PMID 40054624 |
| 2001 | Randomised controlled trial | Antiplatelet and anticoagulant effects of "HN-11 500," a selective thromboxane receptor antagonist | Thrombosis research | PMID 11457465 |
| 2020 | Randomised controlled trial | Effect of Curcumin Supplementation on Exercise-Induced Oxidative Stress, Inflammation, Muscle Damage, and Muscle Soreness | Journal of dietary supplements | PMID 31025894 |
| 2019 | Randomised controlled trial | [Clinical observation on time-effect of electroacupuncture for idiopathic facial paralysis] | Zhongguo zhen jiu = Chinese acupuncture & moxibustion | PMID 31621257 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT07678073 | NA | RECRUITING | 68 | Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation |
| NCT06105229 | N/A | UNKNOWN | 60 | Clinical Value of Plasma Humanin in Acute Kidney Injury |
| NCT03431844 | N/A | COMPLETED | 106 | Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.
Reported dosing ranges
No human dosing range for Humanin as a treatment has been published in the supplied evidence set. The available records describe Humanin as a measured biomarker or study topic, so this section cannot provide a dosing chart for patient use 1 2 3 4.
| Source | Population or setting | Humanin exposure studied | What this means for patients |
|---|---|---|---|
| Basereh et al., Scientific Reports, 2025 1 | People with type 2 diabetes in a randomized trial of exercise and astaxanthin-related biology | No Humanin dosing range is provided in the supplied record. | This cannot be used as a Humanin dose recommendation. |
| NCT07678073 2 | Renal transplantation anesthesia research | Humanin and MOTS-c levels are listed as measured study topics. | This is biomarker research, not patient dosing guidance. |
| NCT06105229 3 | Acute kidney injury research | Plasma Humanin is listed as the clinical topic. | This does not establish a treatment dose. |
| NCT03431844 4 | Cardiac operation research | Humanin isoforms in cardiac muscle and blood plasma are listed as study topics. | This does not establish a dose, schedule, or route. |
Why this page should not provide patient dosing instructions
A dose is not just a number. It depends on route, formulation, purity, stability, kidney and liver function, other medications, and the condition being studied. The supplied Humanin records do not provide enough treatment-dose evidence to translate into patient instructions 1 2 3 4.
This is why we do not provide a Humanin dosing protocol here. If a person has questions about peptide research, the safer next step is a clinician conversation, not a dosing decision based on internet claims.
Legal status
Our regulatory log holds no confirmed federal action for Humanin. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.
Safety
The supplied evidence does not establish a consumer safety profile for Humanin as an administered peptide. The main human randomized record provided studies Humanin in relation to exercise, astaxanthin, oxidative stress, inflammation, and type 2 diabetes, but it does not establish safety for Humanin treatment use 1.
Limits of safety data when Humanin is measured rather than prescribed
When a study measures Humanin, it can tell researchers about associations, levels, or possible biological roles. It usually cannot tell patients what happens when Humanin is administered at a specific dose, by a specific route, over a specific length of time.
The registered studies in renal transplantation, acute kidney injury, and cardiac operation settings list Humanin as a measured or evaluated topic, not as a clearly established consumer treatment in the supplied records 2 3 4. That leaves major safety questions unanswered.
- Adverse effects: not established from the supplied Humanin treatment evidence.
- Contraindications: not established from the supplied Humanin treatment evidence.
- Long-term safety: not established from the supplied Humanin treatment evidence.
- Pregnancy, breastfeeding, cancer history, autoimmune disease, kidney disease, and liver disease: these require clinician review because the supplied records do not define safety in these groups.
Interactions
No dedicated drug-interaction studies for Humanin as an administered treatment are included in the supplied evidence set. That is not reassurance; it means the interaction profile is not defined from these records 1 2 3 4.
A clinician would still want to review medications and conditions that could affect risk. This includes diabetes drugs, blood pressure medications, anticoagulants, immunosuppressants, kidney disease, liver disease, pregnancy status, and any history of cancer or immune disease.
For metabolic health, this matters because Humanin is discussed in a type 2 diabetes research context, while other treatments used for weight management and glucose biology have their own known risks and monitoring needs. Do not combine peptides, supplements, or prescription treatments without clinician oversight.
How to obtain it legally
Humanin is not offered by Chia. We are saying that plainly because this page is meant to help you understand the evidence, not steer you toward a treatment we do not provide.
A clinician evaluation is the right setting for questions about experimental or biomarker-focused peptides. That evaluation may include your goals, diagnosis history, current medications, allergies, pregnancy status, lab results, kidney and liver health, and whether the question is about symptoms, prevention, performance, or curiosity.
What a clinician can review: goals, medications, conditions, and lab context
A clinician can help separate three different questions: what Humanin is, what the research measures, and whether any action is appropriate for you. The supplied evidence supports Humanin as an active research topic, including type 2 diabetes biology, kidney-injury contexts, renal transplantation, and cardiac operation research 1 2 3 4.
If your main goal is mitochondrial or metabolic health, it may help to read about better-characterized categories first. Our articles on MOTS-c, MOTS-c peptide research, and broader mitochondrial-derived peptides explain related research without turning biomarker science into treatment promises.
What a research-chemical vendor is not
A research-chemical vendor is not a clinician, does not evaluate your medical history, and does not replace a licensed pharmacy. If a product is sold without a real medical evaluation, you may not know its identity, sterility, strength, storage conditions, or impurity profile.
At Chia, treatments we do offer start with a 100% online health questionnaire and a licensed US provider review. A prescription is never guaranteed. For Chia treatments that are compounded, medications are made by US state-licensed 503A compounding pharmacies and shipped to the patient’s door when clinically appropriate; compounded drugs are not FDA-approved.
How does Humanin compare with other mitochondrial peptides?
Humanin and MOTS-c are both discussed within the mitochondrial-derived peptide field, but they should not be treated as interchangeable. The supplied Humanin evidence supports cautious discussion of biomarker and mediator research, while MOTS-c has its own separate evidence base and regulatory questions.
Humanin, MOTS-c, and mitochondrial-derived peptides
Mitochondrial-derived peptides are often discussed together because they are linked to mitochondrial signaling. But each peptide needs its own evidence review. A finding about MOTS-c does not prove a Humanin effect, and a Humanin biomarker study does not prove a MOTS-c treatment effect.
| Peptide or category | How it is discussed | What to be careful about |
|---|---|---|
| Humanin | A mitochondrial-derived peptide also called HN; in the supplied records, it is mainly measured in biomarker or mediator research 1 2 3 4. | Do not infer dosing, benefit, or safety from biomarker measurement. |
| MOTS-c | Another mitochondrial-derived peptide discussed in metabolic and mitochondrial research; read more in our MOTS-c guide. | Do not apply MOTS-c findings to Humanin. |
| Mitochondrial-derived peptides | A broader research category that includes Humanin and MOTS-c; see our overview of mitochondrial-derived peptides. | The category name does not prove that every peptide has the same evidence or risk profile. |
| Mitochondrial peptides more broadly | A wider term used for peptides connected to mitochondrial biology; our mitochondrial peptides guide explains the concept. | Mechanism language can sound more certain than the human evidence actually is. |
FAQ
In the supplied records, Humanin is linked to research topics that include type 2 diabetes, oxidative stress, inflammation, acute kidney injury, renal transplantation, and cardiac operation complications. These links are research contexts, not proof of treatment benefit.
The legal-status section on this page is system-inserted and should be used for status details. This article does not make a separate legal or regulatory claim about Humanin.
Humanin is described as a peptide, meaning a small chain of amino acids. It is commonly grouped with mitochondrial-derived peptides.
The supplied evidence does not show that Humanin causes weight loss. One randomized trial studied Humanin in relation to exercise, astaxanthin, oxidative stress, inflammation, and type 2 diabetes biology, but that is not the same as a proven weight-loss treatment.
No patient dosing range for Humanin as a treatment can be established from the supplied evidence. The records mainly describe Humanin as a measured biomarker or study topic.
The supplied evidence does not establish a consumer side-effect profile for administered Humanin. That means safety, contraindications, long-term effects, and interaction risks remain undefined from this evidence set.
Humanin and MOTS-c are both discussed as mitochondrial-derived peptides, but they are different peptides with different research questions. Findings about one should not be assumed to apply to the other.
No. Chia does not offer Humanin. This page is education-only and is meant to help readers understand the evidence and discuss questions with a clinician.
References
- 1.PMID 41249265 [randomised controlled trial] Basereh A, Khoramipour K, Hosseini N, et al. Redox-sensitive miRNAs and Humanin could mediate effects of exercise and astaxanthin on oxidative stress and inflammation in type 2 diabetes. Scientific reports. 2025.
- 2.NCT07678073 [RECRUITING, NA, n=68] Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation. ClinicalTrials.gov. 2026.
- 3.NCT06105229 [UNKNOWN, N/A, n=60] Clinical Value of Plasma Humanin in Acute Kidney Injury. ClinicalTrials.gov. 2023.
- 4.NCT03431844 [COMPLETED, N/A, n=106] Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation. ClinicalTrials.gov. 2018.
- 5.PMID 11371646 Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proceedings of the National Academy of Sciences of the United States of America. 2001.
- 6.PMID 19956629 Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS ONE. 2009.
- 7.PMID 27690227 Cobb LJ, Lee C, Xiao J, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging. 2016.
- 8.PMID 25738459 Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
